SCHEMBL5445751

SCHEMBL5445751

COc1ccc(S(=O)(=O)N2CCCC(N)C(=O)C2)cc1OC

nearest known ligand 0.62

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GPBAR1 Q8TDU6 1/20 0.62
CYP3A4 P08684 1/20 0.54
CYP2C19 P33261 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
NPSR1 Q6W5P4 1/20 0.54
TSHR P16473 4/20 0.52
MCOLN3 Q8TDD5 2/20 0.50
LMNA P02545 2/20 0.50
CYP19A1 P11511 1/20 0.50
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
ALDH1A1 P00352 2/20 0.49
POLB P06746 2/20 0.49
EPHX2 P34913 1/20 0.49
USP2 O75604 1/20 0.48
GLA P06280 1/20 0.48
MAPK1 P28482 1/20 0.48
HSD17B10 Q99714 1/20 0.48
HTT P42858 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5096486 0.84 HTT (0.59) CYP2C19SMN1; SMN2TSHRALDH1A1HTT
SCHEMBL6558892 0.81 GPBAR1 (0.71) GPBAR1SMN1; SMN2TSHRMCOLN3LMNA
SCHEMBL14565739 0.81 GPBAR1 (0.56) GPBAR1CYP3A4CYP2C19SMN1; SMN2NPSR1
SCHEMBL5444937 0.79 KDM4E (0.52) TSHRMCOLN3MEN1KMT2AALDH1A1
SCHEMBL7209087 0.79 GPBAR1 (0.91) GPBAR1SMN1; SMN2TSHRMCOLN3LMNA
SCHEMBL6367892 0.79 GPBAR1 (0.97) GPBAR1CYP3A4CYP2C19SMN1; SMN2NPSR1
SCHEMBL4187995 0.78 GPBAR1 (0.73) GPBAR1CYP3A4CYP2C19SMN1; SMN2NPSR1
Sb-756050 SCHEMBL4174350 0.78 GPBAR1 (1.00) GPBAR1CYP3A4CYP2C19SMN1; SMN2NPSR1
SCHEMBL7205052 0.78 GPBAR1 (0.88) GPBAR1SMN1; SMN2TSHRMCOLN3LMNA
SCHEMBL5099593 0.77 MAPT (0.53) CYP3A4CYP2C19CYP19A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7196099-B2 Compounds and compositions as cathepsin inhibitors AVENTIS PHARMACEUTICALS INC. (US) 2007-03-27 US claimed
US-20040192742-A1 Novel compounds and compositions as cathepsin inhibitors AVENTIS PHARMACEUTICALS INC. 2004-09-30 US claimed
EP-1436255-A1 NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS Aventis Pharmaceuticals, Inc. (US) 2004-07-14 EP claimed
WO-2003024924-A1 NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS AVENTIS PHARMACEUTICALS INC. (US) 2003-03-27 WO claimed
US-20070135386-A1 Novel Compounds and Compositions as Cathepsin Inhibitors AVENTIS PHARMACEUTICALS INC. (US) 2007-06-14 US disclosed
US-7196099-B2 Compounds and compositions as cathepsin inhibitors AVENTIS PHARMACEUTICALS INC. (US) 2007-03-27 US disclosed
US-20040192742-A1 Novel compounds and compositions as cathepsin inhibitors AVENTIS PHARMACEUTICALS INC. 2004-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192742-A1 Novel compounds and compositions as cathepsin inhibitors CTSS, CTSB, CTSE GPBAR1 2142/4885CYP3A4 1919/4885CYP2C19 1680/4885
US-20070135386-A1 Novel Compounds and Compositions as Cathepsin Inhibitors CTSS, CTSB, CTSE GPBAR1 2142/4885CYP3A4 1919/4885CYP2C19 1680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.